Testing ZG006 for advanced small cell lung cancer and neuroendocrine carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label study is divided into two parts. The first part focuses on dose escalation to assess the safety and tolerability of ZG006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma. Following this, the second part will expand on the recommended doses to evaluate the efficacy and safety of ZG006 specifically in patients with neuroendocrine carcinoma. The study aims to gather important pharmacokinetic data alongside preliminary efficacy results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Fully understand the study and voluntarily sign the informed consent form;
* Male or female 18\~75 years of age;
* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
* Life expectancy ≥ 3 months.

Exclusion Criteria:

* Participants were deemed unsuitable for participating in the study by the investigator for any reason.

Where it's running

• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Shangdi Ning
• Email: ningsd@zelgen.com
• Phone: +86-0512-57309965

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Autologous B7-H3 CAR T Cells in Advanced Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  This study tests a patient’s own B7-H3 CAR T cells to see if they can help people 18 and older whose small cell lung cancer or EPNEC has come back or hasn’t responded to prior treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07509034

• ZG006 plus ZG005 for advanced small cell lung cancer and neuroendocrine carcinoma

  This trial tests whether the combination of ZG006 and ZG005 helps adults with advanced small cell lung cancer or neuroendocrine carcinoma.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Guanzhou, Guangdong · NCT07038096

• Tarlatamab versus standard chemotherapy for pre-treated advanced pulmonary (large-cell) or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas

  This trial tests whether tarlatamab helps adults with DLL3-positive, pre-treated advanced pulmonary (large-cell) or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas compared with standard chemotherapy.

  Recruiting at 40 sites Phase 3 Intergroupe Francophone de Cancerologie Thoracique · Angers and 39 other locations · NCT06937905

• Testing a new treatment for advanced neuroendocrine tumors

  This study is testing a new treatment combining a virus with two cancer drugs to see if it helps people with advanced neuroendocrine tumors feel better and tolerate the treatment well.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT06889493

• Understanding how non-small cell lung cancer transforms into neuroendocrine carcinoma

  This study is trying to see how non-small cell lung cancer changes into a different type called neuroendocrine carcinoma in patients with certain gene mutations who have stopped responding to their current treatments.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06369181

• Dostarlimab treatment for advanced or metastatic cancers with specific genetic markers

  This study is testing if the immunotherapy dostarlimab can help people with certain advanced cancers that have specific genetic markers feel better compared to standard chemotherapy.

  Recruiting Phase 2 Unicancer · Angers and 21 other locations · NCT06333314

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.